Novel CAPN3 variant associated with an autosomal dominant calpainopathy.
CAPN3
NGS
calpainopathy
dominant
myopathy
Journal
Neuropathology and applied neurobiology
ISSN: 1365-2990
Titre abrégé: Neuropathol Appl Neurobiol
Pays: England
ID NLM: 7609829
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
01
10
2019
accepted:
09
04
2020
pubmed:
29
4
2020
medline:
26
10
2021
entrez:
29
4
2020
Statut:
ppublish
Résumé
The most common autosomal recessive limb girdle muscular dystrophy is associated with the CAPN3 gene. The exclusively recessive inheritance of this disorder has been recently challenged by the description of the recurrent variants, c.643_663del21 [p.(Ser215_Gly221del)] and c.598_612del15 [p.(Phe200_Leu204del)], associated with autosomal dominant inheritance. Our objective was to confirm the existence of autosomal dominant calpainopathies. Through our activity as one of the reference centres for genetic diagnosis of calpainopathies in France and the resulting collaborations through the French National Network for Rare Neuromuscular Diseases (FILNEMUS), we identified four families harbouring the same CAPN3 heterozygous variant with supposedly autosomal dominant inheritance. We identified a novel dominantly inherited CAPN3 variant, c.1333G>A [p.(Gly445Arg)] in 14 affected patients from four unrelated families. The complementary phenotypic, functional and genetic findings correlate with an autosomal dominant inheritance in these families, emphasizing the existence of this novel transmission mode for calpainopathies. The mild phenotype associated with these autosomal dominant cases widens the phenotypic spectrum of calpainopathies and should therefore be considered in clinical practice. We confirm the existence of autosomal dominant calpainopathies as an entity beyond the cases related to the in-frame deletions c.643_663del21 and c.598_612del15, with the identification of a novel dominantly inherited and well-documented CAPN3 missense variant, c.1333G>A [p.(Gly445Arg)]. In addition to the consequences for genetic counselling, the confirmation of an autosomal dominant transmission mode for calpainopathies underlines the importance of re-assessing other myopathies for which the inheritance is considered as strictly autosomal recessive.
Substances chimiques
Muscle Proteins
0
CAPN3 protein, human
EC 3.4.22.-
Calpain
EC 3.4.22.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
564-578Informations de copyright
© 2020 British Neuropathological Society.
Références
Zatz M, Starling A. Calpains and disease. N Engl J Med 2005; 352: 2413-23
Guglieri M, Magri F, D’Angelo MG, Prelle A, Morandi L, Rodolico C, et al. Clinical, molecular, and protein correlations in a large sample of genetically diagnosed Italian limb girdle muscular dystrophy patients. Hum Mutat 2008; 29: 258-66
Angelini C, Nardetto L, Borsato C, Padoan R, Fanin M, Nascimbeni AC, Tasca E. The clinical course of calpainopathy (LGMD2A) and dysferlinopathy (LGMD2B). Neurol Res 2010; 32: 41-6
Luo S-S, Xi J-Y, Zhu W-H, Zhao C-B, Lu J-H, Lin J, et al. Genetic variability and clinical spectrum of Chinese patients with limb-girdle muscular dystrophy type 2A. Muscle Nerve 2012; 46: 723-9
Richard I, Broux O, Allamand V, Fougerousse F, Chiannilkulchai N, Bourg N, et al. Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A. Cell 1995; 81: 27-40
Kramerova I, Kudryashova E, Venkatraman G, Spencer MJ. Calpain 3 participates in sarcomere remodeling by acting upstream of the ubiquitin-proteasome pathway. Hum Mol Genet 2005; 14: 2125-34
Duguez S, Bartoli M, Richard I. Calpain 3: a key regulator of the sarcomere? FEBS J 2006; 273: 3427-36
Ono Y, Ojima K, Torii F, Takaya E, Doi N, Nakagawa K, et al. Skeletal muscle-specific calpain is an intracellular Na+-dependent protease. J Biol Chem 2010; 285: 22986-98
Vissing J, Barresi R, Witting N, Van Ghelue M, Gammelgaard L, Bindoff LA, et al. A heterozygous 21-bp deletion in CAPN3 causes dominantly inherited limb girdle muscular dystrophy. Brain 2016; 139: 2154-63
Martinez-Thompson JM, Niu Z, Tracy JA, Moore SA, Swenson A, Wieben ED, et al. Autosomal dominant calpainopathy due to heterozygous CAPN3 C.643_663del21. Muscle Nerve 2018; 57: 679-83
Nallamilli BRR, Chakravorty S, Kesari A, Tanner A, Ankala A, Schneider T, et al. Genetic landscape and novel disease mechanisms from a large LGMD cohort of 4656 patients. Ann Clin TranslNeurol 2018; 5: 1574-87
Straub V, Murphy A, Udd B, Corrado A, Aymé S, Bönneman C, et al. 229th ENMC international workshop: limb girdle muscular dystrophies - nomenclature and reformed classification Naarden, the Netherlands, 17-19 March 2017. Neuromuscular Disord 2018; 28: 702-10
Krahn M, Biancalana V, Cerino M, Perrin A, Michel-Calemard L, Nectoux J, et al. A National French consensus on gene lists for the diagnosis of myopathies using next-generation sequencing. Eur J Hum Genet 2019; 27: 349-52
Krahn M, Lopez de Munain A, Streichenberger N, Bernard R, Pécheux C, Testard H, et al. CAPN3 mutations in patients with idiopathic eosinophilic myositis. Ann Neurol 2006; 59: 905-11
Gorokhova S, Cerino M, Mathieu Y, Courrier S,Desvignes JP, Salgado D, et al. Comparing targeted exome and whole exome approaches for genetic diagnosis of neuromuscular disorders. Appl Transl Genom 2015; 7: 26-31
Zenagui R, Lacourt D, Pegeot H, Yauy K, Juntas Morales R, Theze C, et al. A reliable targeted next-generation sequencing strategy for diagnosis of myopathies and muscular dystrophies, especially for the giant titin and nebulin genes. J Mol Diagn 2018; 20: 533-49
Kaplan J-C, Hamroun D. The 2014 version of the gene table of monogenic neuromuscular disorders (nuclear genome). Neuromuscul Disord 2013; 23: 1081-111
den Dunnen JT, Dalgleish R, Maglott DR, Hart RK, Greenblatt MS, McGowan-Jordan J, et al. HGVS recommendations for the description of sequence variants: 2016 update. Hum Mutat 2016; 37: 564-9
Milic A, Daniele N, Lochmüller H, Mora M, Comi GP, Moggio M, et al. A third of LGMD2A biopsies have normal calpain 3 proteolytic activity as determined by an in vitro assay. Neuromuscul Disord. 2007; 17: 148-56
Mamchaoui K, Trollet C, Bigot A, Negroni E, Chaouch S, Wolff A, et al. Immortalized pathological human myoblasts: towards a universal tool for the study of neuromuscular disorders. Skelet Muscle 2011; 1: 34
Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17: 405-24
Fokkema IFAC, Taschner PEM, Schaafsma GCP, Celli J, Laros JF, den Dunnen JT LOVD vol 2.0: the next generation in gene variant databases. Hum Mutat 2011; 32: 557-63
Landrum MJ, Lee JM, Benson M, Brown GR, Chao C, Chitipiralla S, et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res 2018; 46: D1062-7
Richard I, Roudaut C, Saenz A, Pogue R, Grimbergen J, Anderson L, et al. Calpainopathy-a survey of mutations and polymorphisms. Am J Hum Genet 1999; 64: 1524-40
Fanin M, Fulizio L, Nascimbeni AC, Spinazzi M, Piluso G, Ventriglia V, et al. Molecular diagnosis in LGMD2A: mutation analysis or protein testing? Hum Mutat 2004; 24: 52-62
Sáenz A, Leturcq F, Cobo AM, Poza JJ, Ferrer X, Otaegui D, et al. LGMD2A: genotype-phenotype correlations based on a large mutational survey on the calpain 3 gene. Brain 2005; 128: 732-42
Nascimbeni AC, Fanin M, Tasca E, Angelini C. Transcriptional and translational effects of intronic CAPN3 gene mutations. Hum Mutat 2010; 31: E1658-69
Schröder T, Fuchss J, Schneider I, Stoltenburg-Didinger G, Hanisch F. Eosinophils in hereditary and inflammatory myopathies. Acta Myol 2013; 32: 148-53
Magri F, Colombo I, Del Bo R, Previtali S, Brusa R, Ciscato P, et al. ISPD mutations account for a small proportion of Italian Limb Girdle Muscular Dystrophy cases. BMC Neurol 2015; 15: 172
Ermolova N, Kudryashova E, DiFranco M, Vergara J, Kramerova I, Spencer MJ. Pathogenity of some limb girdle muscular dystrophy mutations can result from reduced anchorage to myofibrils and altered stability of calpain 3. Hum Mol Genet 2011; 20: 3331-45
Liewluck T, Goodman BP. Late-onset axial myopathy and camptocormia in a calpainopathy carrier. J Clin Neuromuscul Dis 2012; 13: 209-13
Bugiardini E, Morrow JM, Shah S, Wood CL, Lynch DS, Pitmann AM, Lynch DS, Pitmann AM, et al. The diagnostic value of MRI pattern recognition in distal myopathies. Front Neurol 2018; 9: 456
Fanin M, Angelini C. Protein and genetic diagnosis of limb girdle muscular dystrophy type 2A: the yield and the pitfalls. Muscle Nerve 2015; 52: 163-73
Scalco RS, Gardiner AR, Pitceathly RDS, Hilton-Jones D, Schapira AH, Turner C, et al. CAV3 mutations causing exercise intolerance, myalgia and rhabdomyolysis: Expanding the phenotypic spectrum of caveolinopathies. Neuromuscul Disord. 2016; 26: 504-10
Cabrera-Serrano M, Ghaoui R, Ravenscroft G, Johnsen RD, Davis MR, Corbett A, et al. Expanding the phenotype of GMPPB mutations. Brain 2015; 138: 836-44
Rubegni A, Malandrini A, Dosi C, Astrea G, Baldacci J, Battisti C, et al. Next-generation sequencing approach to hyperCKemia: a 2-year cohort study. Neurol Genet. 2019; 5: e352
Ye Q, Campbell RL, Davies PL. Structures of human calpain-3 protease core with and without bound inhibitor reveal mechanisms of calpain activation. J Biol Chem 2018; 293: 4056-70
Jia Z, Petrounevitch V, Wong A, Moldoveanu T, Davies PL, Elce JS, Davies PL, Elce JS, et al. Mutations in calpain 3 associated with limb girdle muscular dystrophy: analysis by molecular modeling and by mutation in m-calpain. Biophys J 2001; 80: 2590-6
Ono Y, Torii F, Ojima K, Doi N, , Yoshioka K, Kawabata Y, et al. Suppressed disassembly of autolyzing p94/CAPN3 by N2A connectin/titin in a genetic reporter system. J Biol Chem 2006; 281: 18519-31
Sáenz A, López de Munain A. Dominant LGMD2A: alternative diagnosis or hidden digenism? Brain 2017; 140: e7
Vissing J, Duno M. Reply: dominant LGMD2A: alternative diagnosis or hidden digenism? Brain 2017; 140: e8